Newpath Partners

Prime Medicine is focused on transforming the lives of patients with debilitating diseases through its Prime Editing technology, a next-generation gene editing approach that aims to correct genetic mutations at their precise locations in the genome.

Developing transformative treatments using targeted in vivo delivery of tailored and long-lasting genetic medicines designed to overcome the limitations of today’s therapies.

Autobahn Therapeutics is focused on developing next-generation regenerative medicines for central nervous system (CNS) disorders, utilizing a brain-targeting chemistry platform to create small molecule prodrugs.

Metsera is a clinical-stage biotechnology company focused on engineering, developing, manufacturing, and commercializing a new generation of potent, ultra-long acting, scalable nutrient-stimulated hormone (NuSH) therapies for obesity and related diseases.

Orbital Therapeutics is pioneering RNA medicines designed to reset the immune system and restore health from within, focusing on autoimmune diseases, oncology, next-generation vaccines, and protein therapeutics.

Magnet Biomedicine is advancing precision medicine with its modular TrueGlue™ technology, enabling the systematic discovery of molecular glues for treating human diseases, particularly in cancer and immune disorders.

Eledon Pharmaceuticals is a clinical stage biotechnology company dedicated to developing immune-modulating therapies to protect transplanted organs and reduce the risk of organ rejection, as well as to treat autoimmune and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).

Exo Therapeutics is focused on unlocking intractable drug targets with exosites, utilizing their ExoSight™ platform to develop innovative therapeutic candidates primarily in oncology and inflammation.

nChroma Bio is a genetic medicines company committed to addressing the limitations of existing therapies through a disease-first approach. By combining programmable in vivo delivery and gene-regulating technologies, nChroma is designing optimal solutions to deliver precise, potent and durable treatments for patients with high unmet needs.

Neumora Therapeutics focuses on developing precision medicines for brain diseases. They aim to address the unmet medical needs in neuroscience.

Aera Therapeutics is a biotechnology company leveraging its proprietary protein nanoparticle (PNP) delivery platform to unlock the full potential of genetic medicines. Aera’s platform, based on endogenous human proteins, is being developed to address the limitations of today’s delivery technologies and to expand the reach of genetic medicines to different tissues and applications, in order to benefit more patients across more disease areas.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Fellowship for early-career scientists run by repeat deep-tech founders, prioritizing technical founder quality, for those who've never written business plans, offering up to $1M and not taking IP rights. SciFounders is run by repeat deep-tech founders who previously built Mammoth Biosciences and Conception. The fund is designed for scientists who have never written a business plan and focuses on technical founder quality over trendy ideas, operating as a long-term partner rather than a fixed-cohort program with no formal end date.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.

Seed and early-stage investor that creates and invests in biotech startup companies, emphasizing company creation.